March 3 (Reuters) - Biotechnology company Dendreon Corp (NasdaqGS ... The Seattle-based company's stock was trading at $3.30 before the bell. (Reporting by Natalie Grover and Esha Dey in Bangalore; Editing by Sriraj Kalluvila)
Prostate cancer drug developer Dendreon is seeking Chapter ... to resign for personal reasons. Shares of Dendreon shed most of their value Monday before markets opened, sinking 67 cents to 27 cents. The stock had slipped below $1 …
Shares of Dendreon, which is based in Seattle, shed most of their value Monday before markets opened, sinking 59 cents to 35 cents. The stock had slipped below $1 earlier this fall and has tumbled most of this year after closing 2013 at $2.99.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. Here are highlights …
Valeant recently closed the sale of Dendreon Pharmaceuticals and used net proceeds to ... Valeant shares rose 59 cents to close at $19.74 on the Toronto Stock Exchange. But the stock remains a shadow of its former self when it traded for …
CBC6mon
Investors can view all of the daily updates for free by visiting: http://stockpreacher.com/StockTalk Today's Trade Alerts include: Broadwind Energy, Inc. , BHP Billiton Ltd. , Citigroup Inc. , Candela Corporation , Dendreon Corporation , …
SEATTLE (AP) -- Dendreon Corp. said Friday that revenue from its prostate cancer therapy Provenge grew 27 percent in the third quarter, and the company's stock jumped 16 percent. Provenge was approved with great fanfare 2 1/2 years …
Dendreon -- a biotech company that receives a lot of attention on Fool.com and is hotly debated as a stock -- has recently announced ... report today by clicking here now. The article Dendreon's Big New Push originally appeared on …
The first cancer vaccine, known as Provenge ... are being developed by other companies around the world. But with their stock skyrocketing following the announcement, right now, Dendreon has much to celebrate.